Original language | English |
---|---|
Pages (from-to) | 972-974 |
Number of pages | 3 |
Journal | The Lancet Neurology |
Volume | 19 |
Issue number | 12 |
DOIs | |
State | Published - Dec 2020 |
Externally published | Yes |
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: The Lancet Neurology, Vol. 19, No. 12, 12.2020, p. 972-974.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - The necessity of diplomacy in brain health
AU - Dawson, Walter D.
AU - Bobrow, Kirsten
AU - Ibanez, Agustin
AU - Booi, Laura
AU - Pintado-Caipa, Maritza
AU - Yamamoto, Stacey
AU - Tarnanas, Ioannis
AU - Evans, Timothy
AU - Comas-Herrera, Adelina
AU - Cummings, Jeffrey
AU - Kaye, Jeffrey
AU - Yaffe, Kristine
AU - Miller, Bruce L.
AU - Eyre, Harris A.
N1 - Funding Information: WDD reports personal fees from AARP, Commonwealth Fund, Insights to Illuminate, Cognitive Solutions, Oregon Health Care Association, Splaine Consulting, and Mather, outside the submitted work; AI reports grants from FONCyT-PICT 2017-1818 & 2017-1820, FONDAP 15150012, Interamerican Development Bank (IDB), Alzheimer's Association GBHI ALZ UK-20-639295, and the Multi-Partner Consortium to Expand Dementia Research in Latin America, supported by NIH NIA R01 AG057234, Alzheimer's Association (SG-20-725707), Tau Consortium, and Global Brain Health Institute, outside the submitted work; JC reports grants from NIH–NIGMS, NIH, and NIH–NINDS; personal fees from Keep Memory Alive, during the conduct of the study; personal fees from Acadia, Actinogen, AgeneBio, Alkahest, Alzheon, Annovis, Avanir, Axsome, Biogen, Cassava, Cerecin, Cerevel, Cognoptix, Cortexyme, EIP Pharma, Eisai, Foresight, Green Valley, Grifols, Karuna, Nutricia, Orion, Otsuka, Probiodrug, ReMYND, Resverlogix, Roche, Samumed, Samus Therapeutics, Third Rock, Signant Health, Sunovion, Suven, and United Neuroscience pharmaceutical and assessment companies, and the Alzheimer Drug Discovery Foundation; and other from ADAMAS, BioAsis, MedAvante, QR Pharma, and United Neuroscience, outside the submitted work. In addition, JC has a patent Neuropsychiatric Inventory (NPI) with royalties paid and is the Chief Scientific Advisor of CNS Innovations and a Board member of Keep Memory Alive; KY serves on DSMBs for Eli Lilly and a National Institute on Aging-sponsored study, is a board member of Alector, and is also a member of the Beeson Scientific Advisory Board and the Global Council on Brain Health; HAE reports personal fees from CNSdose, Scioto Biosciences, Prodeo, and Altoida, outside the submitted work; KB, LB, MP-C, SY, IT, AC-H, TE, JK, and BLM declare no competing interests.
PY - 2020/12
Y1 - 2020/12
UR - http://www.scopus.com/inward/record.url?scp=85096223869&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(20)30358-6
DO - 10.1016/S1474-4422(20)30358-6
M3 - Letter
C2 - 33212057
AN - SCOPUS:85096223869
SN - 1474-4422
VL - 19
SP - 972
EP - 974
JO - The Lancet Neurology
JF - The Lancet Neurology
IS - 12
ER -